BOSTON– Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target well-validated but hard-to-drug targets, today announced the appointment of John Throup, Ph.D. as Senior Vice President, Head of Development.
“John is joining Jnana at a pivotal inflection point for the company,” said Joel Barrish, Ph.D., co-founder, President and Chief Scientific Officer of Jnana Therapeutics. “His leadership and expertise will be critical as we prepare to advance our lead program for PKU into clinical development and progress a promising pipeline of programs addressing hard-to-drug targets for immune-mediated diseases and oncology.”
Dr. Throup joins Jnana from Bristol Myers Squibb (BMS) where he was most recently Vice President and Development Lead responsible for leading the development of assets in the Immunology pipeline across early and late development. Most recently, Dr. Throup led the development of the TYK2 inhibitor deucravacitinib from preclinical to NDA and MAA submission. Prior to his time at BMS, Dr. Throup spent 15 years at GlaxoSmithKline (GSK) in operational and strategic leadership roles across the R&D organization. Dr. Throup received his Ph.D. in molecular microbiology from the University of Nottingham, UK.
“This is an exciting time to be joining Jnana. I look forward to advancing potential first-in-class therapeutics derived from Jnana’s proprietary, high-throughput enabled RAPID platform, including their lead PKU program, into clinical development and ultimately to patients,” said Dr. Throup.
